Submissions from 2020
Biological activity of weekly ONC201 in adult recurrent glioblastoma patients, Yazmin Odia and Minesh Mehta
Full Text Restricted – Available from BHSF IP or login only
Early imaging marker of progressing glioblastoma: a window of opportunity, Yazmin Odia and Minesh Mehta
Full Text Restricted – Available from BHSF IP or login only
Recent Health Care Expenditure Trends Among Adult Cancer Survivors in United States, 2009-2016, Muni Rubens, Anshul Saxena, Sankalp Das, Chintan Bhatt, Emir Veledar, Peter McGranaghan, Ana Viamonte Ros, Yuliya Linhares, Yazmin Odia, Michael Chuong, Rupesh Kotecha, and Minesh Mehta
Full Text Restricted – Available from BHSF IP or login only
Submissions from 2019
EBV-positive primary CNS lymphoma restricted to the conus medullaris in an immunocompetent host, Matthew Hall, Lyle Feinstein, Sergio Gonzalez-Arias, and Yazmin Odia
Full Text Restricted – Available from BHSF IP or login only
First clinical experience with DRD2/3 antagonist ONC201 in H3 K27M-mutant pediatric diffuse intrinsic pontine glioma: a case report, Matthew Hall, Yazmin Odia, Doured Daghistani, and Minesh Mehta
Pediatric and adult H3 K27M-mutant diffuse midline glioma treated with the selective DRD2 antagonist ONC201, Matthew Hall, Yazmin Odia, and Minesh Mehta
Full Text Restricted – Available from BHSF IP or login only
Core curriculum guidelines for a required clinical neurology experience, Yazmin Odia
Open Access
Targeted treatment of papillary craniopharyngiomas harboring BRAF V600E mutations, Yazmin Odia
Full Text Restricted – Available from BHSF IP or login only
Submissions from 2017
Comprehensive Genomic Profiling of Esthesioneuroblastoma Reveals Additional Treatment Options, Yazmin Odia
Full Text Restricted – Available from BHSF IP or login only
BRAF-V600E mutant papillary craniopharyngioma dramatically responds to combination BRAF and MEK inhibitors, Ashley Roque and Yazmin Odia
Full Text Restricted – Available from BHSF IP or login only
Submissions from 2016
Gangliocytomas and Gangliogliomas: Review of Clinical, Pathologic and Genetic Features, Yazmin Odia
Open Access
Widely metastatic atypical pituitary adenoma with mTOR pathway STK11(F298L) mutation treated with everolimus therapy, Yazmin Odia
Full Text Restricted – Available from BHSF IP or login only